Search

Your search keyword '"Mughal T"' showing total 191 results
Start Over Author "Mughal T"
191 results on '"Mughal T"'

1. Phytochemical screening, antimicrobial activity, in vitro and in vivo antioxidant activity of Berberis lycium Royle root bark extract

Author

Mughal, T. A., primary, Ali, S., additional, Hassan, A., additional, Kazmi, S. A. R., additional, Saleem, M. Z., additional, Shakir, H. A., additional, Nazer, S., additional, Farooq, M. A., additional, Awan, M. Z., additional, Khan, M. A., additional, Andleeb, S., additional, Mumtaz, S., additional, Tahir, H. M., additional, and Gulzar, N., additional

Published
2024
Full Text
View/download PDF

6. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

Author

Chung, J H, Pavlick, D, Hartmaier, R, Schrock, A B, Young, L, Forcier, B, Ye, P, Levin, M K, Goldberg, M, Burris, H, Gay, L M, Hoffman, A D, Stephens, P J, Frampton, G M, Lipson, D M, Nguyen, D M, Ganesan, S, Park, B H, Vahdat, L T, Leyland-Jones, B, Mughal, T I, Pusztai, L, O’Shaughnessy, J, Miller, V A, Ross, J S, and Ali, S M

Published
2017
Full Text
View/download PDF

10. AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

Author

Martinelli, G, Santoro, A, Gambacorti Passerini, C, Polo, S, Solomon, S, Mukherjee, S, Lech-Maranda, E, Levy, M, Wierzbowska, A, Calbacho-Robles, M, Marconi, G, Giannini, M, Cano, I, Minana, L, Acuna-Cruz, E, Angelosanto, N, Mughal, T, Galleu, A, Blotta, S, Ravandi, F, Montesinos, P, Polo, SV, Solomon, SR, Levy, MY, Giannini, MB, Minana, LT, Mughal, TI, Martinelli, G, Santoro, A, Gambacorti Passerini, C, Polo, S, Solomon, S, Mukherjee, S, Lech-Maranda, E, Levy, M, Wierzbowska, A, Calbacho-Robles, M, Marconi, G, Giannini, M, Cano, I, Minana, L, Acuna-Cruz, E, Angelosanto, N, Mughal, T, Galleu, A, Blotta, S, Ravandi, F, Montesinos, P, Polo, SV, Solomon, SR, Levy, MY, Giannini, MB, Minana, LT, and Mughal, TI

Abstract

Context: Mutations in the FLT3 tyrosine kinase and in IDH1/IDH2 (collectively IDHm) co-occur in up to 30% of adults with acute myeloid leukemia (AML). SEL24/MEN1703 is an orally available, first-in-class, dual PIM/FLT3 kinase inhibitor. Preliminary results from the phase 1/2 first-in-human DIAMOND-01 trial (NCT03008187) demonstrated antitumor activity of single-agent SEL24/MEN1703 in adult patients with relapsed/refractory (R/R) IDHm AML, where 3 of 8 IDHm patients responded. Objective: To report the first safety and efficacy results from an additional expansion cohort of the DIAMOND-01 trial in 20 patients with R/R IDHm AML. Design: DIAMOND-01 is a phase 1/2, open-label, multicenter study consisting of 2 parts: dose escalation and cohort expansion, including an additional expansion cohort (IDHm) that is ongoing. Patients: Patients with R/R IDHm AML and no standard therapeutic options were eligible. Intervention(s): Patients received the recommended dose of 125 mg SEL24/MEN1703 orally, once daily for 14 days over a 21-day cycle until disease progression or unacceptable toxicity. Main Outcome Measure(s): The number and frequency of adverse events (AEs; primary) and overall response rate (ORR; secondary). Results: As of 10 January 2022, 14 patients were enrolled in the IDHm cohort. Seven patients had IDH2, 1 had IDH1/2, and 4 had IDH1 mutations. Two patients had a concomitant FLT3-ITD mutation. Safety data (N=12) showed that grade ≥3 TEAEs (≥10% of patients) were pneumonia (33%) and asthenia (17%), both unrelated to the study drug. Of the 7 patients who completed ≥1 treatment cycle and had ≥1 post-baseline assessment or clear disease progression, ORR was 28.6%; 1 patient achieved a complete response with incomplete blood count recovery at cycle 3 and underwent hematopoietic stem cell transplant, and 1 patient had a partial response at cycle 4 (confirmed at cycle 7 and still on treatment). Among the 7 remaining patients, 3 discontinued before completion of cycle 1 with

Published
2022

15. Evaluation of chemopreventive and chemotherapeutic effect of Artemisia vulgaris extract against diethylnitrosamine induced hepatocellular carcinogenesis in Balb C mice

Author

Ali, S., primary, Ejaz, M., additional, Dar, K. K., additional, Nasreen, S., additional, Ashraf, N., additional, Gillani, S. F., additional, Shafi, N., additional, Safeer, S., additional, Khan, M. A., additional, Andleeb, S., additional, Akhtar, N., additional, and Mughal, T. A., additional

Published
2020
Full Text
View/download PDF

21. Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Author

Barlesi, F., Paz-Ares, L., Page, D., Shewade, A., Lambert, P., Mughal, T., Gay, L., Khorshid, M., Arnieri, B., Capra, W., Foser, S., Mascaux, C., Bubendorf, L., Wang, L., Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Published
2018
Full Text
View/download PDF

22. ASPERGILLUS PAKISTANICUS: MICROSCOPIC AND PHYLOGENETIC ANALYSIS OF A NEW ENTOMOPATHOGENIC FUNGI ISOLATED FROM THE SOIL OF THE CHANGA MANGA FOREST, PAKISTAN.

Author

ABRAR, A., MUGHAL, T. A., SARWAR, S., ONEEB, M., MALIK, K., and SAIF, S.

Subjects
ENTOMOPATHOGENIC fungi, MICROSCOPY, ASPERGILLUS, SCANNING electron microscopy
Abstract

Changa Manga forest is a man-made forest in Pakistan. The soil properties of this forest serve an ideal habitat for a vast variety of entomopathogenic fungi. A number of entomopathogenic fungi were isolated from the soil samples collected from the Changa Manga Forest using Galleria bait method during this investigation. Among these isolated fungi, Aspergillus pakistanicus was found to be morphologically and phylogenetically different from closely related Aspergillus species thus described as a new species. The fungal species was identified on the basis of colony morphology; light microscopy; scanning electron microscopy and by molecular analysis. Macroscopic and microscopic comparison with other species of the respective genus along with sequencing of 18S rRNA genes confirmed its uniqueness and supports its recognition as a novel species. Its angular ornamented conidia and separate clade in the phylogenetic tree support it as a new taxa. A detailed description, microscopic images, and comparison with morphologically and phylogenetically similar species are presented. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Author

Barlesi, F., primary, Paz-Ares, L., additional, Page, D., additional, Shewade, A., additional, Lambert, P., additional, Mughal, T., additional, Gay, L., additional, Khorshid, M., additional, Arnieri, B., additional, Capra, W., additional, Foser, S., additional, Mascaux, C., additional, Bubendorf, L., additional, and Wang, L., additional

Published
2018
Full Text
View/download PDF

25. Advances in the biology and therapy of chronic myeloid leukemia: Proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

Author

Van Etten, R, Mauro, M, Radich, J, Goldman, J, Saglio, G, Jamieson, C, Soverini, S, GAMBACORTI PASSERINI, C, Hehlmann, R, Martinelli, G, Perrotti, D, Scadden, D, Skorski, T, Tefferi, A, Mughal, T, Mughal, T., GAMBACORTI PASSERINI, CARLO, Van Etten, R, Mauro, M, Radich, J, Goldman, J, Saglio, G, Jamieson, C, Soverini, S, GAMBACORTI PASSERINI, C, Hehlmann, R, Martinelli, G, Perrotti, D, Scadden, D, Skorski, T, Tefferi, A, Mughal, T, Mughal, T., and GAMBACORTI PASSERINI, CARLO

Abstract

Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately. © 2013 Informa UK, Ltd.

Published
2013

27. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

Author

Chavan, S S, primary, He, J, additional, Tytarenko, R, additional, Deshpande, S, additional, Patel, P, additional, Bailey, M, additional, Stein, C K, additional, Stephens, O, additional, Weinhold, N, additional, Petty, N, additional, Steward, D, additional, Rasche, L, additional, Bauer, M, additional, Ashby, C, additional, Peterson, E, additional, Ali, S, additional, Ross, J, additional, Miller, V A, additional, Stephens, P, additional, Thanendrarajan, S, additional, Schinke, C, additional, Zangari, M, additional, van Rhee, F, additional, Barlogie, B, additional, Mughal, T I, additional, Davies, F E, additional, Morgan, G J, additional, and Walker, B A, additional

Published
2017
Full Text
View/download PDF

28. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

Author

Stein, CK, Pawlyn, C, Chavan, S, Rasche, L, Weinhold, N, Corken, A, Buros, A, Sonneveld, Pieter, Jackson, GH, Landgren, O, Mughal, T, He, J, Barlogie, B, Bergsagel, PL, Davies, FE, Walker, BA, Morgan, GJ, Stein, CK, Pawlyn, C, Chavan, S, Rasche, L, Weinhold, N, Corken, A, Buros, A, Sonneveld, Pieter, Jackson, GH, Landgren, O, Mughal, T, He, J, Barlogie, B, Bergsagel, PL, Davies, FE, Walker, BA, and Morgan, GJ

Published
2017

29. Chronic myeloid leukemia: Reminiscences and dreams

Author

Mughal, T, Radich, J, Deininger, M, Apperley, J, Hughes, T, Harrison, C, GAMBACORTI PASSERINI, C, Saglio, G, Cortes, J, Daley, G, GAMBACORTI PASSERINI, CARLO, Daley, G., Mughal, T, Radich, J, Deininger, M, Apperley, J, Hughes, T, Harrison, C, GAMBACORTI PASSERINI, C, Saglio, G, Cortes, J, Daley, G, GAMBACORTI PASSERINI, CARLO, and Daley, G.

Abstract

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people’s lives. This tribute provides an outline of the remarkable story of chronic myeloid leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman.

Published
2016

30. Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma

Author

Janku, F., primary, Vergilio, J.A., additional, Salhia, B., additional, Fanale, M., additional, Oki, Y., additional, Huang, H., additional, Westin, J., additional, He, J., additional, Nahas, M., additional, Mughal, T., additional, Miller, V., additional, Stephens, P., additional, Raina, A., additional, Garrido-Laguna, I., additional, Meric-Bernstam, F., additional, Ross, J., additional, and Liang, W., additional

Published
2016
Full Text
View/download PDF

31. Chronic myeloid leukemia: reminiscences and dreams

Author

Mughal, T. I., primary, Radich, J. P., additional, Deininger, M. W., additional, Apperley, J. F., additional, Hughes, T. P., additional, Harrison, C. J., additional, Gambacorti-Passerini, C., additional, Saglio, G., additional, Cortes, J., additional, and Daley, G. Q., additional

Published
2016
Full Text
View/download PDF

32. Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6(th) Post-ASH International CML and Myeloproliferative Neoplasms Workshop

Author

van Etten R. A., Mauro M., Radich J. P., Goldman J. M., Saglio G., Jamieson C., Gambacorti Passerini C., Hehlmann R., Perrotti D., Scadden D. T., Skorski T., Tefferi A., Mughal T. I., SOVERINI, SIMONA, MARTINELLI, GIOVANNI, van Etten R.A., Mauro M., Radich J.P., Goldman J.M., Saglio G., Jamieson C., Soverini S., Gambacorti-Passerini C., Hehlmann R., Martinelli G., Perrotti D., Scadden D.T., Skorski T., Tefferi A., and Mughal T.I.

Subjects
T315I MUTANT, hemic and lymphatic diseases, BCR-ABL EXPRESSION, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, STEM-CELLS, IMATINIB, BCR-ABL1
Abstract

Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.

Published
2013

33. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Author

Mughal, T. I., primary, Cross, N. C. P., additional, Padron, E., additional, Tiu, R. V., additional, Savona, M., additional, Malcovati, L., additional, Tibes, R., additional, Komrokji, R. S., additional, Kiladjian, J.-J., additional, Garcia-Manero, G., additional, Orazi, A., additional, Mesa, R., additional, Maciejewski, J. P., additional, Fenaux, P., additional, Itzykson, R., additional, Mufti, G., additional, Solary, E., additional, and List, A. F., additional

Published
2015
Full Text
View/download PDF

34. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

Author

Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, Salem, Ziad, Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, and Salem, Ziad

Abstract

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

Published
2013

35. Chronic myeloid leukemia--some topical issues

Author

Mughal, T., Cortes, J., Cross, N. C. P., Donato, N., Hantschel, O., Jabbour, E., Kantarjian, H., Melo, J. V., Skorski, T., Silver, R. T., Goldman, J. M., Mughal, T., Cortes, J., Cross, N. C. P., Donato, N., Hantschel, O., Jabbour, E., Kantarjian, H., Melo, J. V., Skorski, T., Silver, R. T., and Goldman, J. M.

Published
2011
Full Text
View/download PDF

36. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

Author

Mughal, T, Radich, J, Van Etten, R, Quintás Cardama, A, Skorski, T, Ravandi, F, Deangelo, D, GAMBACORTI PASSERINI, C, Martinelli, G, Tefferi, A, DeAngelo, D, Tefferi, A., GAMBACORTI PASSERINI, CARLO, Mughal, T, Radich, J, Van Etten, R, Quintás Cardama, A, Skorski, T, Ravandi, F, Deangelo, D, GAMBACORTI PASSERINI, C, Martinelli, G, Tefferi, A, DeAngelo, D, Tefferi, A., and GAMBACORTI PASSERINI, CARLO

Published
2011

45. PLANT WASTE UTILIZATION AS ECOFRIENDLY SORBENTS FOR REMOVAL OF REACTIVE DYES FROM WASTEWATER.

Author

Shahzadi, A., Nosheen, S., Kiran, S., Riaz, S., Mughal, T. A., and Shahid, L.

Subjects
WASTE products, REACTIVE dyes, POTATO waste, INDUSTRIAL wastes, SORBENTS, GREEN roofs, AGRICULTURAL wastes
Abstract

ABSTRACT: Present work was focused on the removal of reactive dyes involving management of agro-waste(chickpea pods, pea pods, potato peels, onion peels and eucalyptus leaves) directly and their conversion to green biosorbents. Dye removal efficiency was monitored by UV-Visible spectrophotometer and the adsorption process was evaluated by scanning electron microscopy(SEM) as well. Maximum dye removal(99%) was obtained from chickpea and pea pods while as a natural biosrbents they remove selected dye up to 24.5% and 28.5% respectively. Continuous monitoring showed that decolorization efficiency of selected biosorbent has a direct relationship with contact time. Synergistic effect was observed between green biosorbent and chitosan. Overall findings of present work confirmed that activated carbon of chickpea and pea pods could be an effective and environment benign(green) adsorbent to remove reactive dyes from industrial effluents. [ABSTRACT FROM AUTHOR]

Published
2020

48. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

Author

Mughal TI, Vaddi K, Sarlis NJ, and Verstovsek S

Subjects
Medicine (General), R5-920
Abstract

Tariq I Mughal,1 Kris Vaddi,2 Nicholas J Sarlis,2 Srdan Verstovsek31Tufts University School of Medicine, Boston, MA, 2Incyte Corporation, Wilmington, DE, 3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Myelofibrosis (MF) is a rare chronic BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homologue 1)-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival. The clinical manifestations of MF include splenomegaly, consequent to extramedullary hematopoiesis, cytopenias, and an array of potentially debilitating abdominal and constitutional symptoms. Dysregulated Janus kinase (JAK)-signal transducer and activator of transcription signaling underlies secondary disease-associated effects in MF, such as myeloproliferation, bone marrow fibrosis, constitutional symptoms, and cachexia. Common fatal complications of MF include transformation to acute leukemia, thrombohemorrhagic events, organ failure, and infections. Potential complications from hepatosplenomegaly include portal hypertension and variceal bleeding, whereas extramedullary hematopoiesis outside the spleen and liver – depending on the affected organ – may result in intracranial hypertension, spinal cord compression, pulmonary hypertension, pleural effusions, lymphadenopathy, skin lesions, and/or exacerbation of abdominal symptoms. Although allogeneic stem cell transplantation is the only potentially curative therapy, it is suitable for few patients. The JAK1/JAK2 inhibitor ruxolitinib is effective in improving splenomegaly, MF-related symptoms, and quality-of-life measures. Emerging evidence that ruxolitinib may be associated with a survival benefit in intermediate- or high-risk MF suggests the possibility of a disease-modifying effect. Consequently, ruxolitinib could provide a treatment backbone to which other (conventional and novel) therapies may be added for the prevention and effective management of specific MF-associated complications.Keywords: extramedullary hematopoiesis, JAK inhibitor, myelofibrosis, myeloproliferative neoplasm, ruxolitinib

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results